Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: JoF who wrote (27521)	11/13/1999 3:01:00 PM
From: hoffy	Respond to of 108040

BLSI might be an interesting small biotech company with a lot of promise. It was written up in Business week and also will be in an upcoming issue of Newsweek mag. Here's the hi-lights from the article: ================================= ATTENTION DEFICIT: IS IT IN THE GENES: Over the years doctors have blamed the condition (ADHD) on dysfunctional home lives, brain damage at birth or food additives. All have been disproved and now they know it is caused by genetically induced imbalance of the brain chemical Dopamine. Boston Life Science (BLSI) has develped an agent, Altropane, that binds to the brain cells to create dopamine. Altropane is already in the final stage of clinical trials as a diagnosis agent for parkinsons disease, cause when the brain cells that produce dopamine die off. AN accurate AHDH test would likely be in huge demand. Studies have shown that 3 to 9.5% of all children of school age have the disease. The disease is very hard to diagnose and it is many times mis-diagnosed and not treated at all. ================================ An accurate test and treatment of the disease would be huge. The article states some numbers which are great. BLSI may capitalize big and big a big winner from this level.